According to scieists, cancer in humans and dogs is very similar, which helps to develop effective treatmes for humans.
According to RCO News Agency, Positive results from clinical tests have been achieved an immune treatme in dogs with bone cancer to build a drug to treat children with bone cancer. This shows how the use of genetic similarity between humans and dogs can be useful for both species.
According to the New Atlaic, the field is called “comparative oncology” and is the study of natural cancers in animals such as dogs and cats as a model for the treatme of human diseases.
Animal cancers that appear spoaneously have common properties with human cancers, including bone cancer, prostate and breast cancer, non -Huchkin lymphoma and melanoma.
New York -based OS Therapies Biotechnology focuses on the developme of immune therapy for bone cancer and other solid tumors and uses “comparative cancer” to achieve its goal.
The company has recely announced that a subsidiary, OS Animal Health, has founded a treatme called OST-HER2 to treat dogs for bone cancer treatme using clinical trial data for quick tracking for children with this type of cancer.
“Bone cancer is the most common cancer among dogs that affects more than 40,000 dogs in the United States every year,” says Paul Romness, CEO and head of the company. We now now have a clear business opportunity to dramatically improve health results in this deadly cancer through “OS-HER2” commercial production process.
HER2 treatmes target cancers exposed to the growth factor of the epidermis 2 (HER2), which include breast, esophageal, lung, ovarian, pancreatic cancers as well as bone cancers. These cancers produce high levels of HER2 protein that accelerate the growth and expansion of the tumor.
Treatme of “Ost-HER2” using a modified Listeria Monocytogenes bacteria to provide DNA therapy to cells stimulates the strong immune system response and causes T cells to target protein.
While bone cancer can appear in any bone in the body of the dogs, it usually appears in the bones of the body weight, which is invasive and maligna and often expands to the lungs.
Tumor removal and sometimes extinction is a common treatme of this cancer, while chemotherapy with surgery is also performed to improve survival time by reducing the risk of metastasis.
The rece clinical trial of Ost-Her2 treatme by OS Therapies in dogs with bone cancer published in the journal Molecular Therapy has shown that the treatme preves or delays amputation, slows down tumors and metastasis growth and improves survival.
The results show that the “OST-HER2” treatme is a less aggressive and more targeted approach to treating this invasive cancer.
In a stateme released after the release of the experimeal data, Romans said: “My dream has been that” Ost-Her2 “has poteially able to change the standard of bone cancer care and poteially restrict the need for amputation or the initial tumor removal with surgery.
“With today’s data, we believe that we are taking the initial steps to do so, because our comparative oncology approach as a result of the 5 % genetic ideity between human and dog bone cancer makes us believe that there is a significa poteial for translating this data io human beings,” he said.
Bone cancer, like dogs, is the most common primary cancer in humans, and like dogs can occur in any bone in humans, but it is more likely to form in long bones.
In January 2025, Ost reported the results of Phase 2’s human clinical tests with “Ost-HER2” for bone cancer that were extended to the lungs and were fully surgically removed.
Participas were between 12 and 39 years old. This treatme created a significa statistical result in 12 -moh survival without EFS eve. The EFS eve is defined as a recurrence and return of metastatic bone cancer.
In addition, the “Ost-HER2” method had a positive and significa effect on overall survival.
The findings of this study have not yet been reviewed or published.
Researchers in the study say we are very pleased with these results of our Phase 2 clinical trial, as they show that paties treated with “Ost-Her2” have achieved the primary end of the 12-moh recurrence.
According to them, the strong safety index shown in the study also supports the use of “Ost-Her2” in a population that currely has no approved treatme.
This new treatme as a treatme for bone cancer in children has received US Food and Drug Administration approval (FDA) and European Drug Agency (EMA)
The end of the message
(tagstotranslate) Bone Cancer (T) Cancer Treatme
